1. Home
  2. WVE vs HPP Comparison

WVE vs HPP Comparison

Compare WVE & HPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • HPP
  • Stock Information
  • Founded
  • WVE 2012
  • HPP 1997
  • Country
  • WVE Singapore
  • HPP United States
  • Employees
  • WVE N/A
  • HPP N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • HPP Real Estate
  • Sector
  • WVE Health Care
  • HPP Finance
  • Exchange
  • WVE Nasdaq
  • HPP Nasdaq
  • Market Cap
  • WVE 915.6M
  • HPP 1.0B
  • IPO Year
  • WVE 2015
  • HPP 2010
  • Fundamental
  • Price
  • WVE $6.97
  • HPP $2.94
  • Analyst Decision
  • WVE Strong Buy
  • HPP Hold
  • Analyst Count
  • WVE 17
  • HPP 9
  • Target Price
  • WVE $19.94
  • HPP $2.96
  • AVG Volume (30 Days)
  • WVE 2.4M
  • HPP 6.9M
  • Earning Date
  • WVE 11-11-2025
  • HPP 11-11-2025
  • Dividend Yield
  • WVE N/A
  • HPP N/A
  • EPS Growth
  • WVE N/A
  • HPP N/A
  • EPS
  • WVE N/A
  • HPP N/A
  • Revenue
  • WVE $93,946,000.00
  • HPP $792,977,000.00
  • Revenue This Year
  • WVE N/A
  • HPP N/A
  • Revenue Next Year
  • WVE $10.02
  • HPP $1.20
  • P/E Ratio
  • WVE N/A
  • HPP N/A
  • Revenue Growth
  • WVE N/A
  • HPP N/A
  • 52 Week Low
  • WVE $5.28
  • HPP $1.78
  • 52 Week High
  • WVE $16.74
  • HPP $5.56
  • Technical
  • Relative Strength Index (RSI)
  • WVE 29.71
  • HPP 60.38
  • Support Level
  • WVE $7.12
  • HPP $2.87
  • Resistance Level
  • WVE $7.76
  • HPP $3.10
  • Average True Range (ATR)
  • WVE 0.51
  • HPP 0.13
  • MACD
  • WVE -0.32
  • HPP 0.01
  • Stochastic Oscillator
  • WVE 0.57
  • HPP 64.13

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About HPP Hudson Pacific Properties Inc.

Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.

Share on Social Networks: